TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic C. elegans

• Main Authors: Bird, T.D (Author), Currey, H.N (Author), Dirk Keene, C. (Author), Hincks, J.C (Author), Kraemer, B.C (Author), Latimer, C.S (Author), Liachko, N.F (Author), Stair, J.G (Author)
• Format: Article
• Language: English
• Published: Company of Biologists Ltd 2022
• Subjects: Alzheimer's disease; amyloid β (Aβ); C. elegans; proteotoxicity; tau; TDP-43
• Online Access: View Fulltext in Publisher

 While amyloid (A) β and tau aggregates define the neuropathology of Alzheimer's disease (AD), TDP-43 has recently emerged as a co-morbid pathology in over half of patients with AD. Individuals with concomitant Aβ, tau, and TDP-43 pathology experience accelerated cognitive decline and worsened brain atrophy, but the molecular mechanisms of TDP-43 neurotoxicity in AD are unknown. Synergistic interactions among Aβ, tau, and TDP-43 may be responsible for worsened disease outcomes. To study the biology underlying this process, we have developed new models of protein co-morbidity using the simple animal C. elegans. We demonstrate that TDP-43 specifically enhances tau but not Aβ neurotoxicity, resulting in neuronal dysfunction, pathological tau accumulation, and selective neurodegeneration. Furthermore, we find that synergism between tau and TDP-43 is rescued by loss-of-function of the robust tau modifier sut-2. Our results implicate enhanced tau neurotoxicity as the primary driver underlying worsened clinical and neuropathological phenotypes in AD with TDP-43 pathology, and identify cell-type specific sensitivities to co-morbid tau and TDP-43. Determining the relationship between co-morbid TDP-43 and tau is critical to understand and ultimately treat mixed pathology AD. © 2022 Company of Biologists Ltd. All rights reserved.